Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06402981
Other study ID # IIT20240464A
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2020
Est. completion date June 2025

Study information

Verified date May 2024
Source Zhejiang University
Contact Jiajia Chen
Phone +8615967109232
Email Jiajiatale0@zju.edu.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational study is to investigate the risk factors of PD-1/PD-L1 inhibitor-associated liver injury, to construct a prediction model for the occurrence of liver injury. The main questions it aims to answer are: - Exploring risk factors for liver injury. - Constructing a Predictive Model for the Occurrence of Liver Injury in PD-1/PD-L1 Inhibitor-Related Liver Injury. - Improving immunotherapy protocols for lung cancer patients.


Description:

PD-1/PD-L1 inhibitors have achieved surprising results in lung cancer treatment and have been approved by the FDA for the treatment of different types of lung cancer. Their overall toxicity is lower than that of standard chemotherapy, but a number of immune-related adverse events have been reported clinically. Liver injury is one of the leading causes of death from adverse events due to PD-1/PD-L1 inhibitors. The occurrence of immune-related liver damage has an important impact on the tumor treatment and prognosis of patients. Most of the current domestic and international studies focus on the overall description and study of PD-1/PD-L1 antibody-related adverse events, and there is no definitive description of the risk factors for the development of immune-related liver injury in lung cancer patients. The aim of this project is to review the clinical data of lung cancer patients treated with PD-1/PD-L1 inhibitors from 2020.01 to 2024.06, to investigate the risk factors of PD-1/PD-L1 inhibitor-associated liver injury, to construct a prediction model for the occurrence of liver injury, and to take measures to prevent the occurrence of fatal immune liver injury, which is of great significance to the immunotherapy of clinical tumor patients. It is of great significance to the immunotherapy of clinical tumor patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 2000
Est. completion date June 2025
Est. primary completion date June 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Lung cancer patients who have received at least one and more PD-1/PD-L1 inhibitor treatments; 2. Gender is not limited, age 18-80 years old Exclusion Criteria: 1. Severe liver injury prior to immunotherapy (elevation of transaminases, alkaline phosphatase, and glutamyl aminotransferase more than 5 times the upper limit of normal). 2. Patients who, in the opinion of the investigator, are not suitable for participation in the study.

Study Design


Intervention

Other:
High risk prediction model for liver injury
Risk Prediction Model for Liver Injury After Use of PD-1/PD-L1 Inhibitors

Locations

Country Name City State
China The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary liver injury The occurrence of immunosuppressant-associated liver damage was determined according to criteria set by the Common Terminology Criteria for Adverse Events (CTCAE 5.0). 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT06244550 - Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors N/A
Completed NCT01089426 - Omegaven Treatment of Parenteral Nutrition (PN) Induced Liver Injury N/A
Recruiting NCT05229328 - Study on the Establishment of a System for Early Warning and Prognostic Evaluation of Patients With Sepsis
Recruiting NCT06080308 - Liver Ischemia-reperfusion Injury and Clinical Data Analysis
Recruiting NCT05155358 - Study on the Establishment of a System for Early Warning and Prognostic Evaluation of Patients With Heat Stroke
Terminated NCT04004884 - Liver Safety Assessment During Ulipristal Acetate Treatment for Uterine Fibroids (LISA)
Recruiting NCT01802996 - Evaluate the Efficacy of Magnesium Isoglycyrrhizinate in the Prevention of Chemotherapy Related Acute Liver Injury Phase 4
Active, not recruiting NCT05882214 - Metabolic Changes Induced by NMN in Healthy Subjects With Acute Binge Drink N/A
Completed NCT04934384 - The Role of Prehospital eFAST in Accelerating Time to Diagnostics or Definitive Treatment in the Emergency Department
Recruiting NCT03039062 - Serum miR-122 as a Real-time Detection Biomarker of Drug-induced Liver Injury by Chemotherapy N/A
Completed NCT00694499 - Non-Operative Management of High Grade Blunt Hepatic Injury: Clinical Complications and the Role of Collateral Damage N/A
Recruiting NCT04937868 - Developing a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients
Completed NCT06249646 - Contained Hepatic Vascular Injuries Following Liver Trauma
Terminated NCT02915081 - Blue Light Therapy for Liver Surgery N/A
Completed NCT03667157 - Liver Function After Intravenous Methylprednisolone Administration Phase 4
Completed NCT03281265 - A Retrospective Multicenter Study of HBV-related Pre-acute-on-chronic Liver Failure in China N/A
Completed NCT04257240 - Recurrence of Liver Malignancy After Ischemia/Reperfusion Injury
Not yet recruiting NCT02808299 - Liver Injury by Statins in Patients With History of Hepatitis B Virus Infection N/A
Not yet recruiting NCT06258525 - SAMe in Prevention of Oxaliplatin-associated Liver Injury Phase 2
Active, not recruiting NCT06298318 - Metabolic Changes in Healthy Subjects With Acute Binge Drink N/A